Recent Updates
Recently added Catalysts
MNKD Positive Sentiment

MannKind to Present at Upcoming Investor Conferences

Key Takeaway: MannKind Corporation announced its participation in several upcoming investor conferences, where CEO Michael Castagna and CFO Chris Prentiss will provide updates. The conferences include the Wells Fargo Health Care Conference, Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. Live audio webcasts and recorded versions will be available on their website.
Price reaction · baseline $4.52 (2025-08-27 close) · hit after-hours · clean, no other MNKD news in the window
day 0 close · peak
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • MannKind is actively participating in multiple investor conferences.
  • Updates will be shared by the CEO and CFO, indicating transparency.
  • The company focuses on innovative inhaled therapeutic products.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.2%
average across 10 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Technosphere Insulin
Phase 1 · Healthy Volunteers

Full Press Release Details

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) --MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind’s Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences:

Wells Fargo Health Care Conference (Boston)Wednesday, September 3, 4:30 p.m. ET

Cantor Global Healthcare Conference (New York)Thursday, September 4, 9:45 a.m. ET

H.C. Wainwright 27th Annual Global Investment Conference (New York)Tuesday, September 9, 11:30 a.m. ET

Morgan Stanley 23rd Annual Global Healthcare Conference (New York)Tuesday, September 9, 2:35 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at:https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKindMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visitmannkindcorp.comto learn more, and follow us onLinkedIn,Facebook,XorInstagram.

Frequently Asked Questions

When will MannKind present at investor conferences?

MannKind will present at investor conferences on September 3, 4, and 9, 2025.

Who will represent MannKind at the conferences?

CEO Michael Castagna and CFO Chris Prentiss will represent MannKind.

Where can I find the live webcasts of the presentations?

Live webcasts will be available on MannKind's investor website.

What is MannKind's focus in the biopharma industry?

MannKind focuses on developing inhaled therapeutic products for endocrine and lung diseases.

Last updated: Aug 27, 2025